FDA Drug Safety Board To Meet Every Six Weeks
This article was originally published in The Pink Sheet Daily
Executive Summary
The board discussed FDA's recent action on fentanyl transdermal patches (J&J's Duragesic and generics) and Purdue's Palladone (hydromorphone extended-release) during a July 27 meeting, FDA's meeting summary says.
You may also be interested in...
A Brief But Memorable Tenure: Former US FDA Commissioner Lester Crawford Dies At 83
Crawford’s time as permanent FDA commissioner lasted less than three months and ended in scandal, but with that stint and his longer stretches as acting commissioner, he oversaw the agency through several historic moments that continue to influence the current regulatory environment.
FDA Drug Safety Oversight Board Should Have More Independent Outside Advisors, Cmte. Says
Board Executive Director Susan Cummins maintains that as a "management tool," the DSOB must run in a different way from a public advisory committee.
FDA Drug Safety Oversight Board Should Have More Independent Outside Advisors, Cmte. Says
Board Executive Director Susan Cummins maintains that as a "management tool," the DSOB must run in a different way from a public advisory committee.